Weight Loss Drugs - weight loss information

With weight loss craze on the rise, people are resorting to various diet pills available in the market. Acomplia, a recently launched diet pill is creating waves in the ever-growing weight loss market. It is developed by Sanofi-Aventis, a large cap French pharma. Acomplia is a short-term obesity management, which is to be used in alliance with a weight loss schedule.

Read the rest of this entry ... (78 words left)

It's now official. If diet drug Acomplia (rimonabant) is ultimately approved for sale in the United States, the prescription diet pill will go on the U.S. market not as Acomplia but as Zimulti.

Sanofi-Aventis, developer of rimonabant which is now sold in a number of European countries, Argentina and Mexico as Acomplia, has long been coy about what name it intends to use if the FDA approves the diet drug for U.S. sale.

But the pros-and-cons of rimonabant are cheduled to be aired by an FDA advisory panel on June 13th, and the official notice of the hearing published in the Federal Register says the panel will discuss "the efficacy and safety of new drug application (NDA) 21-888, proposed tradename Zimulti (rimonabant)."

The meeting notice published by the FDA Endocrinologic and Metabolic Drugs Advisory Committee also is interesting in that would appear to dash suggestions made by some of Sanofi's favorite financial analysts that the FDA may now approve Acomplia / Zimulti for treatment of type 2 diabetes.

Sanofi-Aventis said that Switzerland''s regulatory body Swissmedic has approved anti-obesity drug Acomplia for sale in the country.

Sanofi-Aventis said the regulator has authorised the use of the drug for "for obese patients (Body Mass Index - BMI - greater than or equal to 30 kg/m2) or for overweight patients (BMI greater than or equal to 27 kg/m2) with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.

Physicians in Switzerland may prescribe the 20 mg once-daily pill along with a light diet and physical activity for obese or overweight patients with at least one associated cardiovascular risk factor and after insufficient weight reduction following physical activity or food adaptation.

Source: http://www.businessportal24.com/

While Sanofi's diet drug Rimonabant (Acomplia / Zimulti) remains stalled at the FDA, a potential competitor currently in phase III trials, Merck's MK-0364, now has an official generic name: Taranabant.

Read the rest of this entry ... (157 words left)